Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Kwality Pharmaceuticals Ltd

Your Vote -

Buy

60.00%

Hold

0.00%

Sell

40.00%

60.00%

5 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Kwality Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Kwality Pharmaceutic - Kwality Pharmaceutical Limited Receives Product Registration Of Cyclophosphamide 1Gm In Mexico

    14 Feb 2025, 1:53PM Kwality Pharmaceuticals Limited receives product registrartion of Cyclophosphamide 1gm in Mexico
  • Kwality Pharmaceutic Q3 net profit up 10.91% at Rs 8.54 cr

    31 Jan 2025, 7:20PM The company reported standalone net profit of Rs 8.54 crore for the quarter ended December 31, 2024 as compared to Rs 7.70 crore in the same period la
  • Kwality Pharmaceutic - Integrated Filing (Financial)

    31 Jan 2025, 7:15PM Integrated filing (Financial) for the quarter and nine months ended December 31,2024 is enclosed
  • Kwality Pharmaceutic - UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024

    31 Jan 2025, 6:54PM UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024
  • Kwality Pharmaceutic - Board Meeting Outcome for SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024

    31 Jan 2025, 6:47PM Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), R
  • Kwality Pharmaceutic has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    21 Jan 2025, 3:10PM As of December 2024, 54.82% is owned by Indian Promoters and 45.17% by Public. <p align=justify> Top five Promoters holding highest number of shares o
  • Kwality Pharmaceutic - KWALITY PHARMA RECEIVED SFDA APPROVAL FOR ITS GENERAL INJECTABLES AND BETA LACTAM (UNIT 1 & 2 IN AMRI

    21 Jan 2025, 10:56AM KWALITY PHARMA RECEIVED SFDA APPROVAL FOR ITS GENERAL INJECTABLES AND BETA LACTAM (UNIT 1 & 2 IN AMRITSAR).
  • Kwality Pharmaceutic - Board Meeting Intimation for Declaring Standalone And Consolidated Unaudited Financial Results For The

    20 Jan 2025, 6:01PM Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 ,inter alia, to consi
  • Kwality Pharmaceutic - Kwality Pharmaceutical Ltd Receives RCGM Approval To Advance For Pre-Clinical Studies Of Erythropoieti

    2 Jan 2025, 1:08PM Kwality Pharmaceuticals Limited receives RCGM Approval to Advance for Pre-Clinical Studies of Erythropoietin.
  • Kwality Pharmaceuticals

    28 Dec 2022 , 10:29AM Kwality Pharmaceuticals has received an acknowledgement from Bulgarian Drug Agency for carrying out an inspection of its cephalosporin and oncology plant in Himachal Pradesh. It had made an EU Compliance application to Republic of Bulgaria for carrying out an inspection of Unit II in Himachal Pradesh, and Republic of Bulgaria accepted the application for EU Audit visit.

Key fundamentals

Evaluate the intrinsic value of Kwality Pharmaceuticals Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 324.064 292.289 225.8491 97.2286 78.5107
Liabilities 324.064 292.289 225.8491 97.2286 78.5107
Equity 10.3762 10.3762 10.3762 10.3762 10.3762
Gross Profit 66.6333 60.2887 171.7244 29.2599 14.113
Net Profit 23.9839 19.4688 120.0466 15.415 8.4315
Cash From Operating Activities 43.3473 42.1877 63.0607 26.3559 5.6344
NPM(%) 7.8 7.75 26.31 5.89 6.07
Revenue 307.1718 250.9947 456.1316 261.5027 138.6838
Expenses 240.5385 190.706 284.4072 232.2428 124.5708
ROE(%) 9.95 8.07 49.8 6.39 3.49

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Kwality Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 809.25 -0.64 11.41 386.86 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 58.19 1.50 237.75 1409.68 14.01 0.88
Bharat Immunological and Biologicals Corporation Ltd 21.32 -1.30 0.00 2926.96 -39.50 0.00
Astec Lifesciences Ltd 654.90 -5.39 0.00 1329.20 -239.30 0.00

Company Info

The Company was originally incorporated as Kwality Pharmaceuticals Private Limited on May 04, 1983 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Further the name of the Company was changed to Kwality Pharmaceuticals Limited vide a fresh certificate of incorporation dated December 28, 2015 issued by the Registrar of Companies, Chandigarh. The Corporate Identification Number is U24232PB1983PLC005426. The Promoters of the Company are Mr. Ramesh Arora and Mr. Ajay Arora. The Company is primarily engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. The Company does not have RoC filings with respect to Form 2 made in the period prior to 2003, in order to ascertain allotments made during the period from May 04, 1983, till March 29, 2003. However, the Company has maintained Register of Members since inception and we have relied on the limited information available in the Minute Book and Register of Members of the Company. The relevant documents are also not available/destroyed at the office of the RoC Chandigarh as certified by Rishi Mittal & Associates, Company Secretaries, dated May 30, 2016. Therefore, the Company is unable to provide any disclosures or make any confirmations on all of the aforementioned matters. The disclosures pertaining to the aforementioned matters currently made in this Prospectus are subject to information readily available from public domains and other limited records. The Registered Office of the Company is situated at Village Nagkalan, Majitha Road, Amritsar - 143601. Major Events and Milestones : 1983 -Incorporation of the Company on May 04, 1983 2007 -Received ISO Certification 2008 -Commencement of new manufacturing unit at Jassur in Himachal Pradesh 2009 -Received status of Star Export House Certificate 2012 -Turnover increased by 75% 2013 -Incorporation of Subsidiary Company in Africa 2014 -Received WHO certification 2016 -Kwality Pharmaceuticals are listed and admitted to dealings on the Exchange in the list of 'MT' Group Securities. 2017 The Company has allotted on October 13, 2017, 51,88,099 Equity Shares of Rs. 10/- each, as Bonus Shares in the ratio of 1:1 to the shareholders whose names appear on the Register of Members/Depositories as on record date i.e. October 12, 2017. 2024 -The Company Received Its First Biological Product Permission For Manufacturing And Sale Of Pegylated-Aspa.

The Company was originally incorporated as Kwality Pharmaceuticals Private Limited on May 04, 1983 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Further the name of the Company was changed to Kwality Pharmaceuticals Limited vide a fresh certificate of incorporation dated December 28, 2015 issued by the Registrar of Companies, Chandigarh. The Corporate Identification Number is U24232PB1983PLC005426. The Promoters of the Company are Mr. Ramesh Arora and Mr. Ajay Arora. The Company is primarily engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. The Company does not have RoC filings with respect to Form 2 made in the period prior to 2003, in order to ascertain allotments made during the period from May 04, 1983, till March 29, 2003. However, the Company has maintained Register of Members since inception and we have relied on the limited information available in the Minute Book and Register of Members of the Company. The relevant documents are also not available/destroyed at the office of the RoC Chandigarh as certified by Rishi Mittal & Associates, Company Secretaries, dated May 30, 2016. Therefore, the Company is unable to provide any disclosures or make any confirmations on all of the aforementioned matters. The disclosures pertaining to the aforementioned matters currently made in this Prospectus are subject to information readily available from public domains and other limited records. The Registered Office of the Company is situated at Village Nagkalan, Majitha Road, Amritsar - 143601. Major Events and Milestones : 1983 -Incorporation of the Company on May 04, 1983 2007 -Received ISO Certification 2008 -Commencement of new manufacturing unit at Jassur in Himachal Pradesh 2009 -Received status of Star Export House Certificate 2012 -Turnover increased by 75% 2013 -Incorporation of Subsidiary Company in Africa 2014 -Received WHO certification 2016 -Kwality Pharmaceuticals are listed and admitted to dealings on the Exchange in the list of 'MT' Group Securities. 2017 The Company has allotted on October 13, 2017, 51,88,099 Equity Shares of Rs. 10/- each, as Bonus Shares in the ratio of 1:1 to the shareholders whose names appear on the Register of Members/Depositories as on record date i.e. October 12, 2017. 2024 -The Company Received Its First Biological Product Permission For Manufacturing And Sale Of Pegylated-Aspa.

Read More

Parent Organisation

Kwality Pharmaceuticals Ltd.

Founded

04/05/1983

Managing Director

Mr.Ramesh Arora

NSE Symbol

FAQ

The current price of Kwality Pharmaceuticals Ltd is

The 52-week high for Kwality Pharmaceuticals Ltd is

The market capitalization of Kwality Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Kwality Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Kwality Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Kwality Pharmaceuticals Ltd shares.

The CEO of Kwality Pharmaceuticals Ltd is Mr.Ramesh Arora, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT